07 Feb 2023 — Nutritional associations have “expressed dismay” following the US Food and Drug Administration’s (FDA) rejection of three citizens’ petitions to legally allow the marketing of cannabidiol (CBD) in dietary supplements.
The dismissal means further delay in finding a regulatory framework for CBD – an ingredient that is rapidly gaining traction across a range of categories that the FDA regulates, spanning supplements, foods, beverages, cosmetics and drugs.